HITABATUMA, H., Papart, P., WAUTHY, J., BARTHOLOME, F., & Ansseau, M. (2011). Le modèle psychologique de Cloninger (TCI) et la dépression. Acta Psychiatrica Belgica, 111 (3), 34-38. |
Papart, P., Ansseau, M., & Bartholomé, F. (2008). Contingent negative variation abnormalities in posttraumatic stress disorder. European Neuropsychopharmacology, 18 (Suppl 4), 481-482. |
Papart, P., Liota, F., Bartholome, F., & Ansseau, M. (September 2006). Cognitive topography imbalance in alcoholism and psychiatric comorbidity. European Neuropsychopharmacology, 16 (Suppl. 4), 496. doi:10.1016/S0924-977X(06)70671-X |
Papart, P., Liota, F., Bartholomé, F., & Ansseau, M. (September 2003). Cognitive topography imbalance in alcoholism. Journal of Psychophysiology, 17 (Suppl 1), 7-8. |
Hansenne, M., Pitchot, W., Pinto, E., Papart, P., & Ansseau, M. (2000). Serotonergic-1a activity and contingent negative variation. Biological Psychology, 52 (3), 259-65. doi:10.1016/S0301-0511(99)00047-2 |
Hansenne, M., Pitchot, W., Pinto, E., Reggers, J., Papart, P., & Ansseau, M. (2000). P300 event-related brain potential and personality in depression. European Psychiatry, 15 (6), 370-7. doi:10.1016/S0924-9338(00)00505-8 |
Papart, P., WEERTS, P., Pinto, E., Hansenne, M., & Ansseau, M. (2000). Relationship between CNV topography and irritability in depression. Journal of Psychophysiology, 14 (Suppl 1). |
Papart, P. (1999). Troubles psychiatriques et dangerosité. Acta Psychiatrica Belgica, 99, 229-238. |
Hansenne, M., PITCHOT, W., Papart, P., & ANSSEAU, M. (1998). Serotonergic modulation of the P300 event related brain potential. Human Psychopharmacology, 13 (4), 239-243. doi:10.1002/(SICI)1099-1077(199806)13:4<239::AID-HUP986>3.0.CO;2-V |
Papart, P., Ansseau, M., & Timsit-Berthier, M. (1997). Influence of Diazepam on Contingent Negative Variation. Human Psychopharmacology, 12, 95-98. doi:10.1002/(SICI)1099-1077(199703/04)12:2<95::AID-HUP841>3.0.CO;2-3 |
Papart, P., Ansseau, M., & Timsit-Berthier, M. (1996). CNV in mood disorders. In Recent advances in event-related brain potential research (pp. 897-900). Elsevier Science. |
Hansenne, M., Pitchot, W., Gonzalez Moreno, A., Papart, P., Timsit-Berthier, M., & Ansseau, M. (1995). Catecholaminergic function and P300 amplitude in major depressive disorder (P300 and catecholamines). Electroencephalography and Clinical Neurophysiology, 96 (2), 194-196. doi:10.1016/0168-5597(94)00317-8 |
Pitchot, W., Ansseau, M., Gonzalez Moreno, A., Lembreghts, M., Hansenne, M., Wauthy, J., Reel, C., Jammaer, R., Papart, P., Sulon, J., & Legros, J.-J. (1995). The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pharmacopsychiatry, 28 (Suppl. 2), 91-92. doi:10.1055/s-2007-979625 |
Papart, P. (1994). Dépression: Intérêt de la variation contingente négative. Dialogue/Depression. |
Ansseau, M., Papart, P., Troisfontaines, B., Bartholome, F., Bataille, M., Charles, G., Schittecatte, M., Darimont, P., Devoitille, J. M., & De Wilde, J. (February 1994). Controlled Comparison of Milnacipran and Fluoxetine in Major Depression. Psychopharmacology, 114 (1), 131-7. doi:10.1007/BF02245454 |
ANSSEAU, M., Gabriëls, A., Loyens, J., Bartholomé, F., Evrard, J. L., De Nayer, A., Linhart, R., Wirtz, J., Bruynooghe, F., Surinx, K., Clarysse, H., Marganne, R., & Papart, P. (1994). Controlled comparison of paroxetine and fluvoxamine in major depression. Human Psychopharmacology, 9 (5), 329-336. doi:10.1002/hup.470090502 |
Ansseau, M., PITCHOT, W., Hansenne, M., WAUTHY, J., Moreno, A. G., Jammaer, R., Réel, C., Lembreghts, M., Papart, P., Gros-Gean, J., Devroye, A., Sulon, J., & Legros, J.-J. (1994). The flesinoxan/5-HT1A receptor challenge and suicidal behavior. European Neuropsychopharmacology, 4 (3), 322-323. doi:10.1016/0924-977X(94)90138-4 |
Papart, P., ANSSEAU, M., & Timsit-Berthier, M. (1994). Contingent negative variation (CNV) in mood disorders. European Neuropsychopharmacology, 4 (3), 323. doi:10.1016/0924-977x(94)90139-2 |
Schittecatte, M., Charles, G., Machowski, R., Dumont, F., Garcia-Valentin, J., Wilmotte, J., Papart, P., PITCHOT, W., WAUTHY, J., Ansseau, M., Pelc, I., & Hoffman, G. (1994). Effect of gender and diagnostic on growth hormone response to clonidine for major depression : A large scale multicenter study. American Journal of Psychiatry, 151 (2), 216-220. doi:10.1176/ajp.151.2.216 |
ANSSEAU, M., Gabriëls, A., Loyens, J., Bartholomé, F., Evrard, J.-L., De Nayer, A. R., Linhart, R., Wirtz, J., Bruynoghe, F., Surinx, K., Clarysse, H., Marganne, R., & Papart, P. (1993). A double-blind comparison of paroxetine and fluvoxamine in major depression. European Neuropsychopharmacology, 3 (3), 323-324. doi:10.1016/0924-977x(93)90099-8 |
ANSSEAU, M., PITCHOT, W., Gonzalez Moreno, A., Papart, P., & WAUTHY, J. (1993). Pilot study of flesinoxan in major depression. Effect on REM latency and body temperature. Human Psychopharmacology, 8 (4), 279-283. doi:10.1002/hup.470080407 |
ANSSEAU, M., PITCHOT, W., Papart, P., Gonzalez Moreno, A., Timsit-Berthier, M., & LEGROS, J.-J. (1993). Intérêt des marqueurs biologiques de dépression dans le choix du traitement antidépressif. Médecine et Hygiène, 51 (1990), 1970-1976. |
ANSSEAU, M., Troisfontaines, B., Papart, P., & von Frenckell, R. (1993). Compulsive personality and serotonergic drugs. European Neuropsychopharmacology, 3 (3), 288-289. doi:10.1016/0924-977X(93)90077-Y |
ANSSEAU, M., PAPART, P., PITCHOT, W., Timsit-Berthier, M., Legros, J.-J., & von Frenckell, R. (1992). Dexamethasone suppression test and prediction of treatment response to selective antidepressants. European Psychiatry, 7 (4), 191-194. |
ANSSEAU, M., PITCHOT, W., Gonzalez-Moreno, A., Papart, P., Gerritsen van der Hoop, R., & Bradford, D. (1992). Flesinoxan, a 5-HT1A agonist, in major depression: Clinical efficacy and effects on rem latency and body temperature (open study). European Neuropsychopharmacology, 2 (3), 313. doi:10.1016/0924-977X(92)90153-Y |
Ansseau, M., Pitchot, W., Papart, P., Gonzalez Moreno, A., Lembreghts, M., & Legros, J.-J. (1992). Neuroendocrine Factors in Affective Disorders. Clinical Neuropharmacology, 15 (Suppl 1 Pt A), 574A-575. doi:10.1097/00002826-199201001-00299 |
PITCHOT, W., Ansseau, M., Réel, C., Gonzalez Moreno, A., Papart, P., & Hansenne, M. (1992). Red blood cell folate and suicidal behavior. European Neuropsychopharmacology, 2 (3), 306-307. doi:10.1016/0924-977X(92)90143-V |
PITCHOT, W., Gonzalez Moreno, A., Ansseau, M., Hansenne, M., & Papart, P. (1992). Clonidine test in bipolar vs unipolar melancholic patients. European Neuropsychopharmacology, 2 (3), 306. doi:10.1016/0924-977X(92)90142-U |
Schittecatte, M., ANSSEAU, M., Charles, G., Machowski, R., Papart, P., PITCHOT, W., & Wilmotte, J. (1992). Growth hormone response to clonidine in male untreated panic patients. Psychological Medicine, 22 (4), 1059-1062. doi:10.1017/s0033291700038630 |
Ansseau, M., Troisfontaines, B., Papart, P., & von Frenckell, R. (28 September 1991). Compulsive Personality as Predictor of Response to Serotoninergic Antidepressants. BMJ: British Medical Journal, 303 (6805), 760-1. doi:10.1136/bmj.303.6805.760 |
Ansseau, M., Devoitille, J.-M., Papart, P., Vanbrabant, E., Mantanus, H., & Timsit-Berthier, M. (1991). Comparison of Adinazolam, Amitriptyline, and Diazepam in Endogenous Depressive Inpatients Exhibiting Dst Nonsuppression or Abnormal Contingent Negative Variation. Journal of Clinical Psychopharmacology, 11 (3), 160-165. doi:10.1097/00004714-199106000-00003 |
Ansseau, M., von Frenckell, R., Cerfontaine, J.-L., & Papart, P. (1991). Pilot Study of Pk 11195, a Selective Ligand for the Peripheral-Type Benzodiazepine Binding Sites, in Inpatients with Anxious or Depressive Symptomatology. Pharmacopsychiatry, 24 (1), 8-12. doi:10.1055/s-2007-1014425 |
Papart, P., ANSSEAU, M., & Timsit-Berthier, M. (1991). Contingent Negative Variation and response to antidepressants. European Neuropsychopharmacology, 1 (3), 461. doi:10.1016/0924-977X(91)90679-O |
PITCHOT, W., ANSSEAU, M., Gonzales Moreno, A., Papart, P., Gerritsen van der Hoop, R., & Bradford, D. (1991). Pilot study of flesinoxan, a 5-HT1A agonist, in major depression. European Neuropsychopharmacology, 1 (3), 436. doi:10.1016/0924-977x(91)90641-7 |
Ansseau, M., Papart, P., Gérard, M.-A., von Frenckell, R., & Franck, G. (1990). Controlled Comparison of Buspirone and Oxazepam in Generalized Anxiety. Neuropsychobiology, 24 (2), 74-78. doi:10.1159/000119464 |
Papart, P., & ANSSEAU, M. (1990). Milnacipran in obsessive-compulsive disorder: Study in one case. Psychiatrie et Psychobiologie, 5 (5), 325-327. |
Papart, P., & Ansseau, M. (1990). Milnacipran et trouble obsessionnel-compulsif: étude d'un cas. Psychiatrie et Psychobiologie, 5 (5), 325-327. |
Papart, P., Ansseau, M., Devoitille, J. M., Mantanus, H., & Timsit-Berthier, M. (1990). Contingent negative variation and severity of depression. In Psychiatry: A world perspective - Volume 2 (pp. 402-408). Elsevier Science Publishers. |
ANSSEAU, M., von Frenckell, R., Papart, P., Mertens, C., De Wilde, J., Botte, L., Devoitille, J.-M., Evrard, J. L., De Nayer, A., Koch‐Bourdouxhe, S., Darimont, P., Lecoq, A., Mirel, J., Couzinier, J. P., Demarez, J. P., & Serre, C. (1989). Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Human Psychopharmacology, 4 (3), 221-227. doi:10.1002/hup.470040308 |
PITCHOT, W., ANSSEAU, M., PAPART, P., Franck, G., & Rorive, G. (1989). Hyponatrémie induite par la carbamazépine et affection rénale : à propos d'un cas. Psychiatrie et Psychobiologie, 4 (4), 235-237. doi:10.1017/S0767399X00002807 |
Ansseau, M., von Frenckell, R., Cerfontaine, J.-L., Papart, P., Franck, G., Timsit-Berthier, M., Geenen, V., & Legros, J.-J. (1988). Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. British Journal of Psychiatry, 153 (1), 65-71. doi:10.1192/bjp.153.1.65 |
ANSSEAU, M., Cerfontaine, J.-L., von Frenckell, R., Charles, G., Papart, P., & Franck, G. (1987). L'index de Newcastle pour le diagnostic de dépression endogène : Comparaison avec les critères de diagnostic pour la recherche de dépression majeure. Encéphale (L'), 13 (2), 67-72. |
Ansseau, M., Legros, J.-J., Mormont, C., Cerfontaine, J.-L., Papart, P., Geenen, V., & Franck, G. (1987). Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology, 12, 231-236. doi:10.1016/0306-4530(87)90009-6 |
Ansseau, M., von Frenckell, R., Cerfontaine, J.-L., Papart, P., Franck, G., Timsit-Berthier, M., Geenen, V., & Legros, J.-J. (1987). Neuroendocrine evaluation of catecholaminergic neurotransmission in mania. Psychiatry Research, 22 (3), 193-206. doi:10.1016/0165-1781(87)90034-5 |
Demey-Ponsart, E., Ansseau, M., Sulon, J., von Frenckell, R., Cerfontaine, J.-L., Papart, P., Franck, G., Geenen, V., & Legros, J.-J. (1987). Diagnostic performance of basal free cortisol/18-hydroxy-11-deoxy-corticosterone (18-OH-DOC) ratio in endogenous depression: comparison with the dexamethasone suppression test. Biological Psychiatry, 22 (8), 947-956. doi:10.1016/0006-3223(87)90004-7 |
Papart, P., & Ansseau, M. (1987). Echelle manie-depression de l'AMDP et inversion maniaque. Psychiatrie et Psychobiologie, II (3). |
Papart, P., Ansseau, M., Cerfontaine, J.-L., & Franck, G. (May 1986). Adinazolam-Induced Mania. American Journal of Psychiatry, 143 (5), 684-685. doi:10.1176/ajp.143.5.684-a |